Aptevo Therapeutics Inc SEC Filings

Bank of America Corporation and two wholly owned subsidiaries — Bank of America N.A. and BofA Securities, Inc. — jointly filed an initial Form 3 reporting beneficial ownership in Aptevo Therapeutics Inc. (APVO). The filing shows a combined indirect holding of 27 shares of Aptevo common stock, held by the subsidiaries and attributable to the parent through ownership of those subsidiaries. The filing notes the reporting owners may have temporarily held voting and dispositive power over additional shares due to short-term stock borrowings, and clarifies the filing is not an admission of acting as a group under Section 13(d).

Point72 entities and Steven A. Cohen disclosed beneficial ownership of 299,944 shares of Aptevo Therapeutics Inc. common stock, representing 9.1% of the class as of the close of business on September 16, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through their management of Point72 Associates, while Mr. Cohen controls those entities. The statement includes a certification that the shares were not acquired to change or influence control of the issuer. The reporting parties executed a joint filing agreement (Exhibit 99.1) and provided principal business address information.

L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 164,300 warrants of Aptevo Therapeutics Inc. The filing amends a prior Schedule 13G and clarifies that the reported 164,300 warrants are subject to a 4.99% beneficial ownership limitation and correspond to 4.99% of Aptevo's common stock based on 3,287,918 shares outstanding as of August 11, 2025.

The amendment notes that it does not include an additional 1,345,075 warrants that are also subject to the 4.99% limitation. The reporting entity is organized in the Cayman Islands; David Feldman and Joel Arber are identified as its directors. The filing includes a certification that the securities were not acquired to influence control of the issuer.

Aptevo Therapeutics disclosed that CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 357,842 shares of common stock, equal to 9.9% of the class. The reported position consists of shares issuable upon exercise of warrants; the filing shows 0 sole voting or dispositive power and 357,842 shared voting and dispositive power for the reporting persons.

The filing cites the company’s proxy indicating 3,224,156 shares outstanding as of June 20, 2025. Heights Capital is identified as the investment manager to CVI and may exercise voting and dispositive power over CVI’s holdings; both reporting persons disclaim beneficial ownership except for their pecuniary interest. The statement includes a certification that the securities were not acquired to change or influence control of the issuer.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, and Waqas Khatri report beneficial ownership of 358,150 shares of Aptevo Therapeutics Inc. common stock (CUSIP 03835L405), representing 9.99% of the class. The reported shares are issuable on exercise of warrants held by the Reporting Persons and are subject to a 9.99% beneficial ownership blocker. The percentage calculation is based on 3,224,156 shares outstanding per the issuer's prospectus dated June 20, 2025, and the holdings are reported as of June 30, 2025. Each Reporting Person disclaims shared voting or dispositive power and reports sole voting and dispositive power over the 358,150 issuable shares. The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Aptevo Therapeutics (APVO) reported a net loss of $12.6 million for the six months ended June 30, 2025 and a three-month loss of $6.2 million, driven by research and development and general and administrative expenses. Cash and cash equivalents were $9.41 million at June 30, 2025, and net cash used in operating activities for the six months was $13.7 million, resulting in an accumulated deficit of $260.2 million.

The company disclosed that substantial doubt exists about its ability to continue as a going concern for the one-year period from issuance. Since quarter-end Aptevo completed multiple equity financings that raised $15.9 million and entered a $25.0 million standby equity purchase agreement, and established an ATM program (originally $50.0 million, prospectus later updated to $8.0 million available under Form S-3 limits). The company also has 12,585,033 common warrants outstanding that could generate additional proceeds if exercised.

Aptevo Therapeutics announced that it furnished a press release reporting its financial results for the period ended June 30, 2025. The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference into the report. The company states the information is being furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws and will not be incorporated by reference into future SEC filings unless expressly referenced. The 8-K itself contains no financial figures or metrics; readers must consult the attached press release for the reported results.